AUSTIN, Texas–(BUSINESS WIRE)–Omniscient Neurotechnology Pty (“o8t™”), a neuroscience company specializing in mapping and quantification of the human brain, announced that its Quicktome™ automated brain mapping platform has won the 2022 South By Southwest® (SXSW) Innovation Award ), which rewards the most exciting technological developments in the connected world. Quicktome has been hailed for its innovative ability to harness AI and machine learning to create a unique and powerful view into brain connections.
“By harnessing artificial intelligence and machine learning, we are generating insights into the complexities of the brain in ways never before possible – and bringing that power to doctors, researchers, therapy developers and technology innovators. around the world,” said Dr. Stéphane Doyen, Chief Data Scientist and co-founder of Omniscient Neurotechnology.
The company is a world leader in a rising branch of neuroscience called “connectomics.” Using advanced analytical techniques, the Quicktome platform can create a precision brain map from a standard MRI – personalized for the individual – in less than an hour. It is the only commercially available software today for mapping the brain’s higher cognitive and emotional regulatory networks. The company develops applications for neurology, mental health and human performance.
In a world first, Quicktome was recently cleared by the US FDA for use by neurosurgeons in planning life-changing brain surgeries. The tool provides neurosurgeons with a unique, personalized map of each patient’s brain networks prior to surgery, which can help surgeons minimize risk and maximize outcomes for their patients.
“It is invigorating to see the tech community share our enthusiasm for connectomic brain mapping and its positive impact on healthcare and humanity. This award from SXSW recognizes the profound importance of the Quicktome platform in unraveling the mysteries of the brain – and reinforces our confidence in our mission to improve the lives of billions of people through connectomics,” said Stephen Scheeler, CEO.
The Quicktome platform was announced as the winner of the AI & Machine Learning category of the award, which evaluates digital systems that replicate learning, problem solving and cognition. SXSW is an annual celebration of ingenuity and a destination for creators and technologists. It brings together pioneers in these fields through conferences and film, interactive media and music festivals.
About the Quicktome™ platform
Quicktome™ is the world’s most advanced digital brain mapping platform that provides physicians, researchers, therapy developers and brain technology innovators with a personalized picture and understanding of an individual’s brain networks.
Such information helps inform physicians before administering precision brain medicine therapies such as neurosurgery; allow researchers to explore the deep complexities of the human brain; enable therapeutic product developers to design more precise treatments; and helping brain technology innovators create new tools to improve brain performance.
An individual’s brain networks are responsible for everything from their ability to speak and move to their thoughts and emotions. Brain maps can help scientists and doctors pinpoint specific locations in individual brains for treatment, research, or augmentation.
To do this, Quicktome analyzes millions of data points from a standard MRI and produces a personalized report connectomics brain mapping in less than an hour, usable on any device. This makes brain mapping completely non-invasive for individuals and convenient for doctors, researchers, therapy developers and innovators.
The launch of the Quicktome platform is a milestone that combines decades of research in connectomics – the study of brain connections – with cutting-edge algorithms and cloud computing. Quicktome has received regulatory clearance in the United States, Canada and Australia for use in neurosurgery.
About Omniscient Neurotechnology
Omniscient Neurotechnology (o8t™) is a neuroscience company focused on brain health and a global leader in the field of connectomics. It’s led by a team of doctors, data scientists and big tech experts who are building digital brain maps to help science better understand, treat and prevent brain health issues. The company’s goal is to use its intelligence-augmenting software to find biomarkers, create diagnostic tools, refine therapeutic targeting and track disease progression. Based in Sydney, Australia, with additional offices around the world, the company is poised to change the future of neuroscience and make advanced brain mapping technology accessible to everyone. To learn more, visit o8t.com.